PetMeds® Announces Fourth Quarter and Fiscal Year 2026 Financial Results

▤ Summary

PetMed Express reported fourth quarter and fiscal 2026 results, with sales falling year over year while losses narrowed in the quarter and widened sharply for the full year. The company cited lower prescription medication sales, goodwill impairment, professional fees, and severance costs as key pressures on results. Management said it completed strategic, operational, and technology initiatives intended to reduce costs and support future growth. PetMeds also pointed to B2B expansion through membership programs and white-label pharmacy fulfillment, including a recently announced agreement with Rural King. The board reviewed unsolicited acquisition proposals but decided to remain independent while staying open to future inbound interest.

▦ Linked Companies